Zelira Therapeutics has announced the University of Western Australia team that undertook a double-blind, placebo-controlled, crossover trial of its ZTL-101 (Zenivol) treatment for chronic insomnia patients has had the results published in peer-reviewed journal Sleep.
The results of the trial, undertaken at the university’s Centre for Sleep Science and published earlier this year, showed patients saw a significant decrease in insomnia after using Zenivol for two weeks relative to a placebo. Chronic insomnia is present in six to 15% of the population.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
